Do IUDs Really Make Your Breasts Bigger?

Hormonal IUDs do not cause permanent breast growth, but they can cause temporary breast swelling, tenderness, and a feeling of fullness that many people interpret as getting bigger. The levonorgestrel-releasing IUD (sold as Mirena, Liletta, Kyleena, and Skyla) delivers a synthetic progestin that reaches breast tissue in small amounts, and breast-related complaints are among the most commonly reported side effects. Copper IUDs, which release no hormones, do not produce this effect. The gap between what the breasts feel like and what is actually happening inside them is where most of the confusion lives.

What Hormonal IUD Users Actually Report

Breast pain and tenderness are not rare complaints among levonorgestrel IUD users. A prospective study tracking women after Mirena insertion found that about 37% reported mild breast pain shortly after placement, with roughly 38% still reporting mild pain at the six-month mark. Moderate and severe breast pain affected a smaller but meaningful share of users as well.¹ That study highlighted mastalgia as the second most common complication tied to IUD use, trailing only abnormal uterine bleeding.

Larger-scale pharmacovigilance data tell a similar story. An analysis of the FDA’s adverse event reporting system found that breast pain was one of the most frequently flagged events for the levonorgestrel IUD, with breast tenderness and breast cysts also showing up at rates higher than expected compared to other drugs in the database.² When your breasts are sore, swollen, and tender, it is easy to conclude they have grown. But pain and puffiness are not the same thing as lasting size change.

Why Hormonal IUDs Affect the Breasts at All

The levonorgestrel IUD is designed to act locally in the uterus, but some hormone inevitably enters the bloodstream. Measurements of levonorgestrel concentration in breast tissue from IUD users found the drug present at very low levels, averaging around 0.26 nanograms per gram of tissue, only slightly above the detection threshold seen in women not using hormonal contraception.³ That is a tiny amount compared to what the uterus sees, but breast tissue is hormone-sensitive, and even small exposures can trigger a response.

Lab research helps explain why. In experiments using both mouse mammary tissue and human breast cell grafts, levonorgestrel was among the progestins that promoted breast cell proliferation. This effect appears tied to levonorgestrel’s androgenic properties: progestins that activate androgen-related pathways triggered a signaling cascade involving a protein called RANKL, which drives cell division in breast tissue. Progestins without androgenic activity did not produce the same effect.⁴ Separately, research on progestin effects in the mammary gland showed that adding a progestin to estrogen therapy boosted growth factor signaling and proliferation markers in breast tissue far more than estrogen alone.⁵

So levonorgestrel can, at least in a controlled lab setting, stimulate breast cells to divide. But the concentrations reaching the breast from an IUD are far lower than those used in lab experiments or delivered by oral contraceptives, which is why the clinical picture tends to involve transient tenderness and swelling rather than permanent tissue growth.

Swelling Versus Actual Growth

The feeling of bigger breasts after IUD insertion most likely reflects fluid retention and mild tissue swelling rather than the creation of new breast tissue. Progestins influence how the body handles fluids. Sex hormones, including synthetic progestins, affect fluid regulation through mechanisms involving the kidneys, blood vessel permeability, and hormone-sensitive receptors throughout the body.⁶ Many women already experience cyclical breast swelling in the days before their period when progesterone levels peak. A hormonal IUD introduces a steady low-level progestin exposure that can mimic or extend that premenstrual puffiness.

Imaging studies reinforce the distinction. A study of premenopausal Korean women using the levonorgestrel IUD found no changes in mammographic breast density, mammogram category, or breast ultrasound findings compared to baseline.⁷ If the IUD were causing meaningful structural breast growth, you would expect at least some shift in density or tissue composition on imaging. The absence of change suggests that what users experience is surface-level swelling and sensitivity, not deeper architectural remodeling.

How Copper IUDs Compare

Copper IUDs release no hormones. They prevent pregnancy through the local effects of copper ions in the uterus, and they do not deliver anything into the bloodstream that would reach breast tissue. Breast tenderness is not a recognized side effect of copper IUDs. In a seven-year head-to-head trial comparing the levonorgestrel IUD to the copper TCu380A, hormonal side effects prompting removal (which can include breast symptoms) were far more common in the hormonal group, accumulating at a rate of about 5.7 per 100 users versus 0.4 per 100 for copper IUD users.⁸

If you are experiencing breast changes and you have a copper IUD, the IUD is almost certainly not the cause. Other explanations, from weight fluctuations to normal hormonal cycling to pregnancy, are worth considering instead.

The Weight Gain Question

Some people wonder whether the perceived breast size increase is actually part of broader weight gain caused by the IUD. The evidence on this is murkier than most people assume, but the bottom line is that hormonal IUDs do not appear to cause significantly more weight gain than copper IUDs.

A study comparing weight change over 12 months among users of the levonorgestrel IUD, the etonogestrel implant, the DMPA injection, and the copper IUD found no statistically significant differences between any of the progestin-only methods and the hormone-free copper IUD after adjusting for age and race.⁹ Another study looking specifically at body composition found that while lean body mass increased in both levonorgestrel and copper IUD users over a year, overall weight and body composition changes did not differ between the groups.¹⁰

One study did find that levonorgestrel IUD users gained an average of 2.9 kilograms over 12 months compared to 1.4 kilograms for copper IUD users, but the difference between the two groups was not statistically significant. That same study noted an interesting detail about what kind of weight was gained: levonorgestrel users showed a gain in fat mass alongside a loss in lean mass, while copper IUD users showed the opposite pattern, though neither group’s body composition shifted dramatically.¹¹ These are small differences, and they sit in the range of normal year-to-year body fluctuation. If your breasts seem bigger, modest weight redistribution could be contributing alongside hormonal swelling, but it is unlikely to be a dramatic shift driven by the device itself.

How Long the Breast Changes Last

For most users, breast tenderness and swelling peak in the first few months after insertion and then gradually settle. The body adjusts to the steady low-dose progestin exposure, and many of the early side effects, including breast symptoms, diminish over time. The prospective study that tracked mastalgia found that pain levels at six months were only marginally different from those at the initial post-insertion check, suggesting that for some women the symptoms do persist beyond the early adjustment period.¹ But beyond six months, clinical experience and prescribing guidance generally indicate that breast symptoms continue to fade.

If breast tenderness or swelling worsens over time rather than improving, or if it develops suddenly months or years into IUD use, that warrants a conversation with a healthcare provider. At that point, the symptom is less likely to be an IUD side effect and more likely to have another cause worth investigating.

When Breast Changes Actually Need Attention

Breast pain on its own is overwhelmingly benign. A systematic review of mastalgia management found that when no abnormality shows up on clinical examination, the standard approach is reassurance, a well-fitting supportive bra, and topical anti-inflammatory gel, which together are usually enough to resolve the issue. Second-line treatments exist for severe or persistent cases, but most breast pain related to hormonal contraception does not reach that threshold.¹²

That said, the FAERS analysis flagged breast cysts as another signal associated with the levonorgestrel IUD.² Cysts are usually harmless fluid-filled sacs, and most resolve on their own. But if you feel a distinct new lump in your breast, whether you have an IUD or not, getting it checked is always the right call. The IUD is not a reason to dismiss a new lump, and it is not a reason to panic about one either.

Oral Contraceptives and Breast Size for Comparison

People sometimes compare IUD breast effects to what happens with the pill. Oral contraceptives deliver much higher systemic hormone levels than a hormonal IUD, and the breast effects tend to be more pronounced. A study of healthy young women found that breast size was strongly and positively correlated with current oral contraceptive use, with measurable increases during specific phases of the cycle in pill users compared to women who had never used oral contraceptives.¹³ Those increases, while measurable, were also temporary and linked to the hormonal exposure rather than to lasting tissue growth.

The comparison matters because it highlights a dose-response relationship. The pill floods the entire body with estrogen and progestin; the hormonal IUD delivers a fraction of that progestin dose, mostly to the uterus. The levonorgestrel reaching breast tissue from an IUD is measurably present but very low, which is consistent with the clinical reality that breast effects from IUDs are typically milder and more often about tenderness than visible size change.³

Why This Side Effect Gets Dismissed and Why It Shouldn’t Be

Breast tenderness and perceived size changes from IUDs sometimes get brushed off in clinical settings as trivial or imagined. The evidence suggests they are neither. When roughly a third of IUD users in a tracking study report breast pain, and when large-scale safety databases flag breast-related events as disproportionately associated with the device, the experience is common enough to merit straightforward acknowledgment.

At the same time, the finding that mammographic density does not change in IUD users is genuinely reassuring.⁷ Increased mammographic density is a recognized risk factor for breast cancer, and the absence of density changes with IUD use suggests the device is not creating a worrying structural shift in breast tissue. So the breast changes you feel are real but are not a sign that something dangerous is happening.

Galactorrhea and Other Uncommon Breast Effects

A small number of hormonal IUD users report galactorrhea, which is unexpected nipple discharge unrelated to breastfeeding. The FAERS database analysis identified galactorrhea as an adverse event signal, though it was reported far less frequently than breast pain or tenderness.² Galactorrhea has many possible causes beyond the IUD, including thyroid issues, certain medications, and pituitary conditions, so if it develops, it is worth a medical evaluation rather than automatically attributing it to the device.

Progestins in general can influence prolactin-related pathways. Research on progestin effects in breast tissue found activation of the prolactin receptor signaling pathway when a progestin was combined with estrogen.⁵ In the context of an IUD delivering very low systemic progestin levels, this pathway activation is unlikely to be clinically significant for most users, but it may partially explain the rare reports of nipple discharge. If you notice discharge that is persistent, bloody, or occurs from only one breast, seek evaluation regardless of IUD status, as those features can indicate conditions unrelated to contraception.

1
PubMed Central. Prevalence of Mastalgia and the complications attributed to it following Mirena intrauterine device insertion: A prospective cohort study
2
Heliyon. Post-marketing safety profile of levonorgestrel-releasing intrauterine system: A real-world disproportionality analysis using the FDA adverse event reporting system (FAERS) database
3
ScienceDirect (Contraception). Breast levonorgestrel concentrations in women using a levonorgestrel-releasing intrauterine system
4
PubMed Central. Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation
5
PubMed Central. Progestin effects on cell proliferation pathways in the postmenopausal mammary gland
6
PubMed Central. Sex hormone effects on body fluid regulation
7
The Journal of Korean Society of Menopause. The Effect of Levonorgestrel-releasing Intrauterine System (Mirena®) on the Mammographic Density and Breast Ultrasonographic Findings in Korean Premenopausal Women
8
PubMed Central. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A
9
PubMed Central. Weight Change at 12 Months in Users of Three Progestin-Only Contraceptive Methods
10
PubMed Central. Changes in Body Composition in Women using Long-acting Reversible Contraception
11
PubMed. Body weight and composition in users of levonorgestrel-releasing intrauterine system
12
PubMed Central. A systematic review of current understanding and management of mastalgia
13
American Journal of Epidemiology. Breast Size in Relation to Endogenous Hormone Levels, Body Constitution, and Oral Contraceptive Use in Healthy Nulligravid Women Aged 19–25 Years